Ownership Capital B.V. Has $45.77 Million Position in Illumina, Inc. (NASDAQ:ILMN)

Ownership Capital B.V. lessened its stake in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 27.1% in the first quarter, according to its most recent filing with the SEC. The fund owned 576,911 shares of the life sciences company's stock after selling 214,276 shares during the period. Illumina comprises about 2.1% of Ownership Capital B.V.'s portfolio, making the stock its 20th largest holding. Ownership Capital B.V. owned 0.36% of Illumina worth $45,772,000 as of its most recent filing with the SEC.

Several other large investors have also modified their holdings of the stock. Diversified Trust Co acquired a new position in shares of Illumina in the 1st quarter valued at $355,000. State of Alaska Department of Revenue lifted its stake in Illumina by 2.5% during the first quarter. State of Alaska Department of Revenue now owns 18,527 shares of the life sciences company's stock valued at $1,469,000 after buying an additional 445 shares in the last quarter. Merit Financial Group LLC boosted its holdings in shares of Illumina by 344.8% in the first quarter. Merit Financial Group LLC now owns 13,036 shares of the life sciences company's stock worth $1,034,000 after buying an additional 10,105 shares during the period. Trexquant Investment LP increased its position in shares of Illumina by 16.7% in the fourth quarter. Trexquant Investment LP now owns 142,977 shares of the life sciences company's stock worth $19,106,000 after acquiring an additional 20,506 shares in the last quarter. Finally, Robeco Institutional Asset Management B.V. raised its holdings in shares of Illumina by 15.1% during the first quarter. Robeco Institutional Asset Management B.V. now owns 516,293 shares of the life sciences company's stock valued at $40,963,000 after acquiring an additional 67,676 shares during the period. 89.42% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on ILMN shares. Morgan Stanley lowered their price objective on shares of Illumina from $136.00 to $100.00 and set an "equal weight" rating on the stock in a research report on Monday, May 12th. Piper Sandler dropped their price target on Illumina from $190.00 to $185.00 and set an "overweight" rating on the stock in a research report on Thursday, May 15th. Guggenheim lowered their target price on Illumina from $122.00 to $114.00 and set a "buy" rating on the stock in a research note on Friday, May 9th. Royal Bank Of Canada reduced their price target on shares of Illumina from $128.00 to $112.00 and set an "outperform" rating for the company in a research report on Tuesday, April 8th. Finally, Stephens restated an "overweight" rating and set a $105.00 price target on shares of Illumina in a report on Tuesday, May 20th. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, Illumina presently has an average rating of "Hold" and a consensus target price of $125.11.

Illumina Stock Performance

Shares of NASDAQ ILMN traded down $0.80 during trading hours on Friday, hitting $99.25. 1,998,677 shares of the stock were exchanged, compared to its average volume of 2,151,831. Illumina, Inc. has a one year low of $68.70 and a one year high of $156.66. The company's 50 day moving average is $86.75 and its 200 day moving average is $96.72. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.86 and a quick ratio of 1.48. The firm has a market capitalization of $15.71 billion, a P/E ratio of -16.35, a P/E/G ratio of 1.96 and a beta of 1.36.

Illumina (NASDAQ:ILMN - Get Free Report) last released its earnings results on Thursday, May 8th. The life sciences company reported $0.97 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.96 by $0.01. Illumina had a positive return on equity of 25.54% and a negative net margin of 22.25%. The firm had revenue of $1.04 billion for the quarter, compared to analyst estimates of $1.03 billion. During the same quarter last year, the firm posted $0.98 EPS. The company's revenue was down 1.4% on a year-over-year basis. On average, research analysts expect that Illumina, Inc. will post 4.51 EPS for the current year.

Insiders Place Their Bets

In other news, CFO Ankur Dhingra purchased 6,100 shares of the business's stock in a transaction that occurred on Monday, May 12th. The stock was purchased at an average cost of $81.21 per share, with a total value of $495,381.00. Following the acquisition, the chief financial officer directly owned 24,906 shares of the company's stock, valued at approximately $2,022,616.26. This trade represents a 32.44% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 2.60% of the company's stock.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.